Our patent discussion with Brink Lindsey and Dan Takash focus on general pharma policy, and the debate about IPR/USPTO functioning. Our experts will discuss vaccines and treatments, how small inventors compete with large drug companies in today’s market, and how patent reform should be part of a post-pandemic economic recovery.